科尔矿业

最新新闻

• 公司公告
  Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE Review
  SZSI · 2026/6/18
• 公司公告
  Tianyu Co., Ltd.: Announcement Regarding the Approval of Active Pharmaceutical Ingredients by the CDE
  SZSI · 2026/5/8
• Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $26.5
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Roth MKM Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 公司公告
  Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE Review
  SZSI · 2026/6/3
• The product of Guobang Pharma's (605507.SH) subsidiary, glyceryl dicaprylate/dicaprate, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE).
  Zhitong Finance · 2026/9/15
• RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  ATB Cormark Capital Markets Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.
  Zhitong Finance · 2026/9/4
• 评级变动
  A Quick Look at Today's Ratings for Coeur Mining(CDE.US), With a Forecast Between $18 to $26.5
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $23
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  BMO Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Raises Target Price to $28.5
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• Guobang Pharma: Glyceryl Dicocoate, a product of its wholly-owned subsidiary, has passed the joint review and approval process with the finished dosage form by the Center for Drug Evaluation (CDE).
  Breakings · 2026/9/15
• 评级变动
  RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 公司公告
  Tianyu Co., Ltd.: Announcement Regarding the Approval of Its Wholly-Owned Subsidiary's Active Pharmaceutical Ingredient by the CDE Review
  SZSI · 2026/9/5
• 公司公告
  Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE Review
  SZSI · 2026/7/14
• 评级变动
  ATB Cormark Capital Markets Downgrades Coeur Mining(CDE.US) to Hold Rating, Cuts Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Scotiabank Initiates Coeur Mining(CDE.US) With Buy Rating, Announces Target Price $28.5
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Scotiabank Initiates Coeur Mining(CDE.US) With Buy Rating, Announces Target Price $27.5
  \u5e02\u573a\u8d44\u8baf · 2026/6/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。